To maintain, produce, authenticate and distribute arthropod vectors and associated reagents for the Emerging Infections Resources Program.

To evaluate the safety, pharmacokinetics and efficacy of macaque-sized CLIP 3D printed intravaginal rings (IVRs) loaded with the potent antiretroviral Islatravir (EFdA) when administered vaginally to pigtailed macaques.

To support implementation of a set of recommendations and a roadmap developed in the "Strengthening Public Health and Community Based Organization (CBO)" Interface report.

To help implement the CDC Foundation programs and activities supporting the Targeted Country Assistance portion of the 2022-2025 Partners’ Engagement Framework.

To improve use of antibiotics in outpatient settings, where most prescribing occurs, by providing antibiotic stewardship resources for state health departments and state Medicaid agencies.

To support the introduction of a change in Burkina Faso’s infant pneumococcal vaccine schedule to include a booster dose and to evaluate the impact of the country’s capacity to control pneumococcal disease among children and adults.

To support efforts to strengthen and expand existing infection prevention control activities in various countries across Sub-Saharan Africa.

To optimize interventions and tools to enable the elimination and eradication of prioritized Neglected Tropical Diseases (NTDs) as identified by the London Declaration.

To test the effects of chlorine and alcohols on infectious norovirus, show the effect of natural compounds on infectivity, persistence of infectious virus in surface water and water microcosms and the effect of heat activation on aqueous viable norovirus.

To further research how viral ovarian tumor protease (vOTU) activity is critical for replication and host tropism of nairoviruses.

To investigate other novel interventions, such as monoclonal antibodies (MAbs) against malaria. An intervention that could prevent malaria in children for a full 12 months in settings of perennial malaria transmission, such as Kenya, holds potential to reduce malaria morbidity and mortality substantially in this population at risk for severe malaria and death.